To almost no one's surprise, another potential treatment in non-small-cell lung cancer (NSCLC) bit the dust as Nexavar (sorafenib) failed to meet the primary endpoint of improving overall survival (OS) in the Phase III MISSION (Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer) trial in patients with advanced relapsed or refractory nonsquamous disease.